Drugmakers Debate Whether Parts of FDA’s Biosimilar Guidance are Unconstitutional

Drugmakers and trade groups have raised questions with two US Food and Drug Administration (FDA) guidance documents on biosimilars, including one explaining how FDA plans to transfer drugs previously approved under new drug applications (NDAs) to be biologic license applications (BLAs).